0000004651 00000 n If a universal approach is no longer an option for content, the same is true of engagement. McKinsey va payer 573 millions de dollars pour régler un contentieux sur les opiacés Kevin Sneader: «Le Covid creusera l’écart entre la Chine et le reste du monde» 1 commentaire Meanwhile, marketing staff will need to further develop their ability to optimize marketing campaigns based on HCP engagement, as well as using CRM data and dashboards to assess the effectiveness of past and future actions. Reinvent your business. Practical resources to help leaders navigate to the next normal: guides, tools, checklists, interviews and more. Innovations developed for new drugs that prove valuable for commercial success will reshape the commercial strategy of the whole company. We analyzed 86 launches scheduled for 2018 onward with expected sales in excess of $300 million. Please email us at: McKinsey Insights - Get our latest thinking on your iPhone, iPad, or Android device. Something went wrong. High prices should not be a barrier to life-saving tools for health systems and economies. 0000001901 00000 n To manage this process and experiment with new methods and ways of working, some companies set up launch situation rooms that pull together data on sales, volume uptake, and other standard metrics with field insights garnered through rep apps to analyze launch performance in real time. In a McKinsey survey of 300 physicians in September 2020, 74 percent of respondents reported noticing their patients delaying necessary care, with conse­quences including an increase in complications from injury or disease, a loss of income from missing work, and a rise in the costs of care. The rejection marked the … US to achieve Covid herd immunity by end of 2021: McKinsey. To do that, they will need to consider a new approach to launches: one that is digital, local, and personalized. Building a fuller view of customer-facing roles and interactions should allow launch leaders to allocate frontline capacity in a more effective and granular manner. 0000008632 00000 n 3. To understand individual physicians’ preferences for interaction frequency and channels, innovative companies are creating data lakes, building predic­tive models, and drawing on unfamiliar data sources—not only customer-relationship-management (CRM) systems, sales records, and quantitative surveys, say, but also claims data for providers at a physician’s office. 0000011422 00000 n A survey conducted by McKinsey in Europe shows that the average number of in-person contacts between HCPs and pharma sales reps was 70 percent lower in September 2020 than before the pandemic. 0000027484 00000 n Learn more about cookies, Opens in new Innovative approaches can yield surprising results. Most transformations fail. In that way, content can be approved and refined within approval cycles of no more than two to four weeks. McKinsey Global Institute. As well as helping to tackle COVID-19 spread by developing and distributing new vaccines and tests, it must continue to deliver innovative therapies and diagnos­tics to clinicians, patients, and healthcare systems—even as R&D, manufacturing, and supply chains are struggling to maintain business as usual. McKinsey provided documents used in legal proceedings regarding OxyContin maker Purdue Pharma, including some that describe its efforts to … hereLearn more about cookies, Opens in new And the epidemic has deepened amid the coronavirus pandemic. McKinsey COVID-19 Survey: EU Physician Experiences, Expectations, and Perspectives on Pharma Engagement; survey in the field in May and September 2020. McKinsey analysis of pharmaceutical-industry data from Evaluate, August 2020. Pharma companies will delay some product launches, and those that go ahead may fall short of expectations, given the impediments to commercializing drugs at the same speed and scale … Forty percent of worldwide drug launches between 2009 and 2017 failed to meet their two-year sales forecasts. 0000012920 00000 n This article draws on insights from a global survey conducted by McKinsey in June 2020 among 101 managers with recently launched drugs that had not reached their peak sales or drugs scheduled for launch between January and June 2020 that had been delayed. McKinsey analyzed products launched from March 2020 or awaiting launch, using data from PHAST (Pharmaceutical Audit Suite) and Evaluate. Never miss an insight. Selon le site Politico et le Canard Enchaîné, le gouvernement a fait appel à ce cabinet américain pour l'aider à organiser sa stratégie de vaccination contre le Covid-19. It is too soon to evaluate the full impact of the COVID-19 pandemic on drug launches. 0000004744 00000 n People create and sustain change. A successful launch must overcome a series of barriers, including intensifying competition, increasing pricing pressure, growing access challenges, and rising expectations among caregivers and patients. Please click "Accept" to help us improve its usefulness with additional cookies. 0000005171 00000 n In parallel, HCPs’ adoption of digital channels and telemedicine has accelerated for interactions with patients and pharma reps alike. It will be critical that each pharma company build new ways to interact with physicians in deep and meaningful ways. The industry faces a dual challenge. Unleash their potential. However, this broad overview masks considerable differences in HCPs’ preferences and expectations. Innovative companies are developing alternative infusion sites, enabling “at home” infusion, and offering guidance on how to minimize risk when visiting health facilities. 5. Purdue Pharma is the owner of OxyContin, a brand name for the painkiller oxycodone. Our mission is to help leaders in multiple sectors develop a deeper understanding of the global economy. McKinsey a notamment conseillé Purdue Pharma, qui a plaidé coupable l'an dernier dans ce dossier, pour l'aider à doper les ventes, selon l'État de New York. 0000009846 00000 n As virtual calls replace in-person visits, reps can foster a sense of proximity with HCPs by learning to make the most of cameras, screen sharing, and other interaction tools. How are HCPs managing COVID-19 infection risk for patients? 5 úÒ§ºï-üÒçÜsÏùsï= ( ºô ¶°Â?XÁ I@ƒqÕ|ør˜üÛ¥0ömÃt¦£}f]ŽÿWÐ,Š…vàn à ÷©A>Z̕»a-|“ϐ%ÇV^‹XþÄk:K—¼ñâ¬ò¾ÈDMï‹pY!^æL½F[ðvõNûè‘È÷›ãçæš7žîÚ¼Wʧs+Zgˆ_‚ÖÒÑ°k%Ü-ÏsÌÌwùžŽWÌïgj§/¥ ×8ÝT›¹RÙÐQv¹Jz>×Ü+ínlÿv—³OÆ;ªÙ‹­£bòë|Í̕|¡câ˜T(ß¡Û6ÒR ƒþ9Ý:N“v¥%x;r×rÎÀ Zh%]|d8ÕËÛU²7U•Š¿tqäõjÆî³r½Þ&c¢Ñ:Y3ô¢ŠHT–ɝ%m’›Ëf{. McKinsey used August 2020 data from Evaluate and estimates from March 2020 or earlier to calculate how the net present value of the 86 drugs changed in the months following the outbreak of COVID-19. McKinsey used August 2020 data from Evaluate and estimates from March 2020 or earlier to calculate how the net present value of the 86 drugs changed in the months following the outbreak of COVID-19. LATEST - Consulting for Purdue Pharma - Floating Bumble. 0000001768 00000 n 3 We use cookies essential for this site to function well. Consulting giant McKinsey has to pay $600 million to settle claims it fed the opioid crisis. cookies, McKinsey_Website_Accessibility@mckinsey.com, some companies set up launch situation rooms. To implement an analytics-based approach to engagement, pharma leaders also need to ensure that two critical enablers are in place: a tech and data backbone to enable seamless integration across channels and data sources, and a platform for run­ning advanced-analytics models to enable leaders to distinguish signals from noise, improve deci­sion making in real time, and optimize messages, channels, and timing in individual HCP interactions. McKinsey COVID-19 Survey: EU Physician Experiences, Expectations, and Perspectives on Pharma Engagement; survey in the field in May and September 2020. A better way to stay relevant is to engage HCPs on the current hot topics in their field—for example, what best practices are emerging in telemedicine? Now an affiliate may profit from treating addicts. McKinsey analysis of pharmaceutical-industry data from Evaluate, August 2020. COVID-19 recovery will be a time of real change and, potentially, risk for pharma companies’ commercial organizations. COVID Response Center. We strive to provide individuals with disabilities equal access to our website. Our work with pharma companies indicates that leaders designing a new strategy should consider paying close attention to five success factors: rapidly personalized content, analytics-enabled engagement, innovative patient channels and services, nimble frontline operations, and closed-loop execution (Exhibit 2). For a pharma company looking to reinvent its commercial model, the launch of new products is a golden opportunity to try out new techniques and gauge their impact before rolling them out more widely. Whether an interaction is face to face or remote, it needs to be scheduled and an agenda shared in advance. McKinsey & Co. said it will pay nearly $600 million to settle allegations that it fueled the nationwide opioid crisis by helping Purdue Pharma push addictive painkillers.. 0 When reps venture back into the field, they will need to address the plurality and access challenges of the new interaction landscape. As a physician’s preferences evolve—both in response to the new product as well as in engagement channels—the model adjusts its recommendations, enabling reps to fine-tune content and channel choices for an audience of one to provide an optimal personalized experience at launch. What do key opinion leaders think about the potential for drug-to-drug interactions with COVID-19 vaccines? 0000018811 00000 n The days of casual appointments and conversations in hallways are over. 139 35 Our mission is to help leaders in multiple sectors develop a deeper understanding of the global economy. Maintaining or adjusting treatment can also be dif­ficult in today’s circumstances, especially for infusions, injections, and other therapies that require attendance at a hospital or clinic. 0000003389 00000 n For each new product launch, best-practice companies compile a set of marketing and medical modules to cover the full spectrum of HCP needs and then ask reps to use their insight into individual physicians to select the modules that best meet their needs. As the use of video, interactive content, and multi­person interactions increases, companies will also need to rethink marketing materials so that they are effective in remote settings. As McKinsey points out, “it is becoming clear that the post-COVID-19 recovery will be a time of real change and, potentially, risk for pharma companies’ commercial organizations.” “It is becoming clear that the post-COVID-19 recovery will be a time of real change and, potentially, risk for pharma companies’ commercial organizations.” Vaccine development, however, is on pace for a surprising milestone. 0000024292 00000 n Capabilities aside, launch programs give companies an opportunity to reassess the setup of their field force. Consulting giant McKinsey & Co. has reached a $573 million settlement with states over its work advising OxyContin maker Purdue Pharma LP and other drug manufacturers to … However, as patients delay care due to the COVID-19 pandemic, the pool of new patients that may have benefited from being treated with a new product is declining as well. Pharmalittle: Switzerland rejects AstraZeneca Covid-19 vaccine; McKinsey to pay $573 million over its role in opioid crisis By Ed Silverman Feb. 4, 2021 Reprints 2. In the United States, for instance, some pharma com­panies found they can predict physicians’ willingness to engage with reps more accurately from foot traffic and credit-card spend in a given zip code than from local state restrictions or COVID-19 infection rates. McKinsey previously came under scrutiny for its role advising Purdue Pharma and the wealth Sackler family that owns the drugmaker. Among major pharma companies, 60 percent are already using telemedicine for trial visits in response to the COVID-19 5 McKinsey Clinical Operations Roundtable Survey, April 2019. crisis and … Le cabinet McKinsey lié à Macron ( RT France, 8 février 2021, 3:07 ) Le 4 janvier, le site Politico révèle que le cabinet McKinsey a conseillé la Fra McKinsey Global Institute. In 50 out of the 86 disrupted launches, companies lowered their expectations by more than 25 percent. 173 0 obj <>stream 0000003815 00000 n our use of cookies, and McKinsey did not respond to requests for comment. As COVID-19 cases continue to spread across the globe, the repercussions in healthcare extend across the value chain from patients and families to clinicians and pharmaceutical companies. The pandemic also had a marked impact on the financial performance of the launches we analyzed. However, it is clear that major shifts in the way that healthcare professionals (HCPs) interact with pharma companies will present a challenge for the traditional launch model, with its reliance on face-to-face meetings with physicians and its “one size fits all” approach to engagement. 6. A rep needs to have something new and compelling to discuss or risks that the meeting might never happen. 0000012135 00000 n 0000006289 00000 n Press enter to select and open the results on a new page. With HCPs’ preferences so variable and changeable, pharma companies need clear, up-to-date per­spectives on each physician’s interests and wishes so they can gear messages to individual needs and concerns. With less time spent traveling and waiting to see HCPs, reps have more capacity to pursue value-added opportunities. McKinsey’s leadership vote reveals cracks in its global partnership McKinsey’s work advising OxyContin maker Purdue Pharma LP and other … To reduce development cycles, content creation and review processes need to be streamlined and simplified. As the survey indicates, the perceived risk of engag­ing with health systems has made many patients wary of face-to-face interactions in all but the most serious cases. Today’s environment makes agile ways of working a necessity. These findings suggest that the traditional pharma commercial model will likely struggle to adapt to a different world. McKinsey Quarterly 0000007754 00000 n COVID-19: Briefing note #44, March 3, 2021 This week in McKinsey research: online learning has underwhelmed. Given the uncertainties triggered by the pandemic and the radical changes in physicians’ preferences and behaviors, replicating successful launch strategies from the past is no longer a safe option. Select topics and stay current with our latest insights, Ready for launch: Reshaping pharma’s strategy in the next normal. Campaigns that prove effective can be scaled up across broader geographies, while ineffective campaigns can be replaced with new campaigns that are tested and, in turn, refined or replaced as needed based on their results. Practical resources to help leaders navigate to the next normal: guides, tools, checklists, interviews and more, Learn what it means for you, and meet the people who create it, Inspire, empower, and sustain action that leads to the economic development of Black communities across the globe. Overall, we estimate that the changes in analyst consensus expectations between March and August 2020 represent a 9 percent decline in the net present value of the 86 drugs—the equivalent of a total loss of some $10 billion globally. Preferences also vary by country. One immediate consequence of the pandemic has been a drastic reduction in pharma companies’ visits to HCPs. Capability-building programs will equip staff with the soft and hard skills— from empathy to proficiency with advanced digital tools—required for success in a rapidly changing launch environment. 0000014985 00000 n (Pixabay) Last week, McKinsey’s 650 global partners turned down CEO Kevin Sneader’s bid for a second three-year term at the helm.